// App-Quantinova.ai

1506 : Identification of Non-Cardiotoxic hERG1 Blockers to Overcome Chemoresistance in Acute Lymphoblastic Leukemias

Researchers

Presenter

  • Serena Pillozzi

Principal Investigators

  • Massimo -Amico

  • Luca Gasparoli

  • Olivia Crociani

  • Matteo Stefanini

  • Kennet Mugridge

  • Wolfang Tiedke

  • Andrea Becchetti

  • Annarosa Arcangeli

Medical Centers

  • Exp. Pathology and Oncology, University of Florence, Firenze, Italy

  • Department of Experimental Pathology and Oncology, University of Florence, florence, Italy

  • Department of Experimental Pathology and Oncology, University of Florence, florence, Italy

  • Department of Biotechnology and Bioscience, University of Milano-Bicocca, Milano, Italy

  • University of Florence, Pisa, Italy

  • Exp. Pathology and Oncology, University of Florence, Firenze, Italy

Locations

  • Italy

Companies

  • BlackSwan Pharma Gmb

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Acute lymphoblastic leukemia

  • Ventricular arrhythmias

  • Cardiotoxicity

Biomarkers

  • Breakpoint Cluster Region

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • C-X-C motif chemokine receptor 4

  • Extracellular signal-regulated kinase

  • Mesenchymal stem cells

  • Stromal cell-derived factor 1

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Erythromycin

  • E.E.S. 400 Oral

  • Sertindole

  • CD160130

  • SDF-1

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved